An evidence-based examination of THC delivery methods, CBD dosing protocols, therapeutic mechanisms, and legal frameworks across DC and Virginia.

The end of a Dutch health ministry supply contract forces the legacy medical cannabis pioneer into bankruptcy, shifting global market dynamics.

Inside the underground dance scenes, cannabis is more than a creative tool—it’s shaping culture, forging community, and redefining lifestyle across the DMV.

TV personality Jason Silva debuts an AI-powered psychedelic film, blurring the lines between altered states, creative tech, and cannabis culture. What does this mean for DMV residents?

Federal cannabis rescheduling is expected to pull producers under the same GMP standards that govern other consumed products, with new equipment rules likely to follow.

A Minnesota state analysis of 1,811 autism patients found sustained reductions in moderate-to-severe anxiety and depression after joining the medical cannabis program, with improvements often lasting at least four months.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

Verano is remodeling its Virginia footprint ahead of a July adult-use launch. Here’s what that timing-first move could mean for DMV consumers, delivery startups and investors.

SHF Holdings Inc. (Safe Harbor Financial) approved a 1-for-12 reverse split, set to take effect Sept. 30, 2026. Here’s what the move means for SHFS shareholders and how DMV investors and cannabis operators should think about capital and delivery models.

State regulators say DEA guidance is essential to align medical cannabis rules with the new Schedule III status—especially for delivery, labeling, and patient access across the DMV.

Federal health officials and clinical experts met in Silver Spring to establish safety, credentialing, and access standards for psychedelic medicines.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

UCSF neuroscientist Robin Carhart-Harris uses brain imaging and clinical trials to explore how psychedelics alter cognition and mood — and what that could mean for patients in the DMV.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

A new documentary spotlights ketamine-assisted therapy for firefighters and raises hard questions about evidence, ethics, and how advocacy should meet science.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

Safety, ethics, dosage, vape pens, and the ibogaine combo—what 5‑MeO‑DMT actually demands, and how DMV readers should navigate it without hype.